$OABI

OmniAb (OABI) held an investor day, highlighting its royalty pipeline, the launch of OmniTides for peptide discovery, and the commercialization of xPloration. The company expects xPloration to generate $2M-$3M in 2026, doubling in 2027 and 2028. OmniAb reaffirmed 2026 revenue guidance of $32M-$36M and expects to be near cash-flow breakeven. The company discussed its licensing models, chicken-based discovery platforms, and ion-channel capabilities, including a partnership with Eli Lilly.

StoneX raised its price target for OmniAb (NASDAQ:OABI) to $6.00 from $4.00, citing new product launches and platform expansion. The stock is currently at $4.47, down 12% over the past week but up 164% over the last year. The company reported Q2 2026 earnings that exceeded expectations and raised its full-year outlook. Analysts maintain a Strong Buy consensus with price targets ranging from $5 to $11.

Stifel maintained a Buy rating and $9.00 price target for OmniAb (OABI), citing its technology platform and upcoming catalysts. The stock has fallen 12.3% in a week but risen 188% in six months. OmniAb reported Q2 2026 earnings beating estimates, with revenue of $13.41M vs. $4.95M expected.

OABI stock rose 10% today with $4.3M in trading volume. Insiders sold 33,314 shares in the past 6 months. 78 hedge funds increased holdings, while 66 decreased. Notable moves include Nomura Holdings adding 4.3M shares and Whitefort Capital Management removing 3.9M shares.

OmniAb, Inc. (NASDAQ: OABI) announced its Investor & Analyst Day on October 6, 2026, in Emeryville, CA. The event will feature presentations on corporate updates, technology innovations, and a Q&A session. Both in-person and virtual participation are available. OmniAb provides discovery research technology for next-generation therapeutics, licensing its platform to pharmaceutical and biotech companies.

OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.

OmniAb (OABI) and Eli Lilly (LLY) announced a global collaboration to develop ion channel therapeutics. Lilly will pay $370M in milestones plus royalties. OABI reported Q2 2026 revenue of $13.4M, up from $3.9M, while LLY reported $23B revenue, up 48% YoY. OABI's model focuses on licensing, while LLY's growth is driven by GLP-1 treatments.

Biotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.

OmniAb Inc. (OABI) shares rose about 18% in premarket after the company increased its 2026 cash forecast. OmniAb now expects $49 million to $53 million in cash and cash equivalents, up from $37 million to $41 million, citing recent license and business-development agreements, including a technology contract with Eli Lilly for its ion-channel program.

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.